The impact of vaccination against influenza and pneumococcal infection on the incidence of acute respiratory viral infections and community-acquired pneumonia in the Central Administrative District of Moscow

Background. Acute respiratory viral infections (ARVI) and pneumococcal infections (PI) annually cause great damage to the health and working capacity of the population, and lead to economic losses for employers and the state. Aim. To study the impact of influenza and PI vaccination coverage on morbidity of ARVI and community-acquired pneumonia (CAP) of the morbidity of population in Central administrative district (CAD) of Moscow. Material and methods. The analysis of official data on monitoring of morbidity from ARVI and CAP was carried out, and information on vaccination of the population against influenza and PI for 2012–2018 was used. Results. In 2018 ARVI accounted for 95.2% of infectious morbidity and the incidence rate was 29853.5 per 100 ths population. Over the period from 2012–2018, the incidence of ARVI and influenza gradually decreased by 2016, but in 2017 the incidence of ARVI was increased to the level of 2012 (+25.3%) however influenza was decreased (-40.9%). In 2018, the incidence of ARVI in adults remained at the level of 2017, and in children there was a decrease (-16.9%). The incidence of influenza in 2018 decreased in both adults (-65.4%) and children (-63.9%). During 2012–2018 the incidence of CAP had a persistent tendency to increase. The coverage of influenza vaccination in CAD population of Moscow has increased annually since 2012 and in 2018 reached 85.5% of children 0–17 years old and 65.5% of adults 18 years and older, and against PI – 46.3% of children and 2.6% of adults. Conclusion. The epidemic circulation of ARVI and influenza had a significant impact on the morbidity of CAD population of Moscow in 2012–2018. Annual vaccination of the population lead to decreasing of influenza incidence but the incidence of pneumonia tended to increase and need to improve prevention.

1. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2017: State Report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2018. 268 p (in Russ.). ISBN 978-5-7508-1626-2].

2. World Health Organization. Regional Office for Europe. WHO European Guidelines for Human Influenza Surveillance. 2009. Available at: http://www.euro.who.int/PubRequest?language=Russian].

3. World health organization. Influenza virus infections in humans (February 2014). S1–2 Available at: http://www.who.int/influenza/gisrs_laboratory/terminology_variant/en/index.html.

4. WHO Regional Office for Europe recommendations for influenza vaccination in the winter season 2017/2018 September 2017 World Health Organization. Regional Office for Europe. Available at: http://www.euro.who.int/pubrequest?language=Russian.

5. Coffin S.E., Zaoutis T.E., Rosenquist A.B., et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119(4):740–748. DOI: 10.1542/peds.2006-2679.

6. Finelli L., Fiore A., Dhara R., et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2009;122(4):805– 811. DOI: 10.1542/peds.2008-1336.

7. Bhat N., Wright J.G., Broder K.R., et al. Influenza-associated deaths among children in the United States, 2003–2004. The New England Journal of Medicine. 2005;353(24):2559– 2567.

8. Chuchalin A.G., Briko N.I., Avdeev S.N., et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19–34 (In Russ.). https://doi.org/10.18093/0869-0189-2019-29-1-19-34.

9. Briko1 N.I., Lobzin Y.V., Baranov A.A., et al. Efficacy of vaccination: main approaches and controversies. Pediatricheskaya farmakologiya. 2014;11(4):8–15 (in Russ.). https://doi.org/10.15690/pf.v11i4.1057.

10. The order of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare of 25.01.11 No. 16 «On Approval of Instructions for Forms of Statistical Observation № 1, 2, 5, 6» (together with the instructions for filling out the forms of federal statistical observation No. 1, 2 «Information on infectious and parasitic diseases», approved by the Order of the Federal State Statistics Service (Rosstat) of 31.12.10 No. 482; federal statistical observation No. 5 «Information on preventive vaccinations», approved by the Order of Rosstat of 31.12.10 No. 482; Federal statistical observation № 6 «Data on numbers of children and adults vaccinated against infectious diseases», approved by Order of Rosstat from 31.12.10 No. 482) (in Russ.). Available at: http://www.consultant.ru/document/cons_doc_LAW_109800/.

11. The order of the Ministry of health of the Russian Federation dated 21.02.14 No. 125n «On approval of the national calendar of preventive vaccinations and vaccination schedules according to epidemic indications» (in Russ.). Available at: http://docs.cntd.ru/document/499086215.

12. Joseph C., Togawa Yu., Shindo N. Bacterial and viral infections associated with influenza. Influenza and other respiratory viruses. 2013; 7 (Suppl. 2): 105–113. DOI: 10.1111/irv.12089.

13. The Federal Service for Supervision of Consumer Rights Protection and Human Welfare, the Department of Rospotrebnadzor for the City of Moscow. State report on the state of sanitary and epidemiological well-being of the population in the city of Moscow in 2018. Moscow, 2019. 247 p. (in Russ.).

14. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. The Lancet Infectious Diseases. 2006;6(5):303– 312. DOI: 10.1016/S1473-3099(06)70466-2.

15. Beadling C., Slifka M.K. How do viral infections predispose patients to bacterial infections? Current Opinion in Infectious Diseases. 2004;17(3):185–191.

16. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clinical Microbiology Reviews. 2006;19(3):571–582. DOI: 10.1016/S1473-3099(06)70466-2.

17. Peltola V.T., Murti K.G., McCullers J.A. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. Journal of Infectious Diseases. 2005;192(2):249–257. DOI: 10.1086/430954.

18. Musher D.M., Manoff S.B., McFetridge R.D., et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Human Vaccines. 2011;7:(9)919–928. DOI: 10.4161/hv.7.9.15996.

19. Cohen R., Levy C., Bingen E., et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. The Pediatric Infectious Disease. 2012;31(3):297–301. DOI: 10.1097/INF.0b013e318247ef84.

20. Matanock A., Lee G., Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥ 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices(ACIP). US Department of Health and Human Services/Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR). 2019;68(46):1069–1075. Available at: https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6846a5-H.pdf